What Makes Successful Biotech Boards
Posted on 02/02/2016
This report looks forensically at correlations between company performance and Board composition. From this we draw out lessons that can be learned from the different approaches to Board constitution and regulation in the UK and the rest of the EU, and draw also on comparators from the USA.
Why? To focus on best practice and to learn more about how to improve the performance of Boards and the companies they lead.
We believe that a Board should be more than the sum of its parts. We looked at the experience, backgrounds, terms-of-office and experience of the non-executives from the ten top performers in the UK and Mainland European Biotech. We then compared their companies against with the “benchmark” BIOG Index.
Our goal is to tease out data that Chairs, Nominations Committees and Investors can use in data driven decision support when building, assessing or refreshing their Boards. What we found supports received wisdom, some surprised us – and may surprise you.